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1. Introduction 
Collagen is a major protein in living organisms and accounts for about one-third of all 
protein in mammalian bodies, including the human body. Recently, collagen peptides have 
been used as foods that take advantage of their tertiary functions. We have been focusing on 
the vasoprotective effect of collagen peptides. 
Chicken collagen hydrolysate (CCH) is obtained by treating chicken feet with enzymes to 
produce an angiotensin-converting enzyme (ACE) inhibitory peptide. Administration of this 
CCH for 12 weeks reduces blood pressure in humans. We therefore investigated the 
mechanism of the vasoprotective effect of CCH. We tested whether prolonged CCH 
treatment of rats or mice would restore endothelial cell function and improve 
proinflammatory cytokine levels. We found that CCH treatment improved the 
vasorelaxation of rat aorta damaged with L-NG-nitroarginine methyl ester , an NO synthesis 
inhibitor. CCH treatment also reduced the serum levels of IL-6, sICAM-1, and TNF-α in an 
atherosclerotic mouse model, C57BL/6.KOR-ApoEsh1.  
These findings indicate the usefulness of collagen peptides as foods promoting anti-
atherogenesis via a vasoprotective effect. 
Years have passed since functional foods and their tertiary function first attracted attention. The 
primary function of foods is to supply the nutrients required to sustain life, and the secondary 
function is to satisfy taste preferences. The tertiary function of foods is to exert biological 
regulatory effects, such as biophylaxis, homeostatic maintenance, and disease prevention, 
which are activated upon food intake. Purified food ingredients that have tertiary functions are 
widely consumed as supplements. Multitudes of supplements are available on today’s market: 
besides common vitamins, minerals, and amino acids, there are catechins, which are antioxidant 
constituents of tea (Katiyar, 2003), soy isoflavones, which have female hormone–like actions 
(Weijer, 2002), and docosahexaenoic acids and eicosapentaenoic acids, which decrease 
triglyceride levels (Tamai, 2004). Collagen is being used widely, not only in supplements but 
also as an ingredient of common food products such as beverages, yogurts, and breads. 
Collagen is a major protein in living organisms and accounts for about one-third of all 
protein in mammalian bodies, including the human body. It forms an extracellular matrix 
that plays a role in the formation of connective tissues and acts as a scaffold for cells, but its 
accumulation declines with age. The majority of the collagen in the body exhibits a triple 
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helix structure; with heating, this structure is lost and the collagen becomes gelatin like. 
Moreover, as a result of enzymatic degradation that eliminates its gelation ability, the 
gelatin increases in solubility and becomes collagen peptides (Fig. 1), which are frequently 
consumed by women, in particular. Collagen peptides are consumed as a food product to 
supply the collagen lost from the body with age, and a substantial number of reports have 
shown that treatment with collagen peptides increases well-being. 
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Fig. 1. Collagen in the body exhibits a triple helix structure but is denatured and becomes 
gelatin-like if heated. Enzyme treatment of denatured collagen produces collagen peptides, 
which are composed of atypical repetitions of -Gly-X-Y-Gly-X-Y- and are consumed as 
functional foods.  
1.1 The tertiary function of collagen peptides 
In recent years, vigorous research has been conducted to elucidate both the mechanism by 
which collagen peptides are absorbed from food into the body and the tertiary functions of 
this protein. Orally administered collagen peptides are transferred to the blood in the form 
of dipeptides or tripeptides, without being completely degraded to amino acids (Iwai, 2009 
and Shigemura,2009). A double-blind placebo-controlled trial has confirmed that collagen 
peptide treatment increases the skin’s moisture content (Ohara, 2009). The primary structure 
of collagen consists of atypical repetitions of -Gly-X-Y- and characteristically includes 
hydroxyproline, which is produced by posttranslational modification. Many studies have 
suggested that this particular sequence enables collagen to exert multiple bioactivities, not 
only in skin and bones, but also in blood vessels, which contain large amounts of collagen 
(Arborelius, 1999). Accordingly, collagen peptides are expected to have tertiary functions 
additional to those already known. 
1.2 Targeting blood vessels 
The blood vessels are referred to as the largest organ in the body, because the vascular 
endothelial cells, which line the vessel lumens, cover an area as large as six tennis courts and 
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weigh 1.5 kg; they are therefore as heavy as the liver. Although blood vessels were once seen 
as simply the “pipes” that circulate blood, it has become increasingly clear that the vascular 
endothelial cells receive signals from organs and control blood supply and the secretion of 
various cytokines on demand (Kato, 2004). 
There are many diseases caused by vascular abnormalities, especially in Japan. According to 
the cause-specific death rates reported by the Ministry of Health, Labor, and Welfare of 
Japan in 2006, death rates due to circulatory system diseases are extremely high: after 
malignant neoplasms (30.4%), cardiovascular diseases account for 15.9% of all deaths and 
cerebrovascular diseases account for 11.8%. From this perspective, protecting the blood 
vessels from disease should increase the quality of life of many people. We therefore took 
advantage of the absorbability of collagen peptides and aimed to develop ones targeting the 
protection of blood vessels. 
1.3 Development of a low-molecular-weight chicken collagen hydrolysate 
Collagen peptides are generally extracted from pig skin or fish scales. However, here we 
used chicken legs as sources of the new collagen peptides. This was because, although 
gelatin is known to be allergenic, our previous study showed that the allergenicity of 
chicken-derived gelatin is the lowest among a number of types (Taguchi, 2002). 
Chicken legs were solubilized by acid treatment and the extracted collagen was processed 
by proteases. The resulting low-molecular-weight collagen peptides were then dried and 
powdered for subsequent use as low-molecular-weight chicken collagen hydrolysate (CCH) 
(Saiga, 2008) (Fig. 2). Our preliminary in vitro experiments showed that CCH strongly 
inhibits angiotensin-converting enzyme (ACE). Production of angiotensin II, a vasopressor, 
is suppressed by the inhibition of ACE in the blood and organs, thereby resulting in a 
hypotensive effect (Gupta, 2010). Because hypertension is closely related to arteriosclerosis, 
the inhibition of blood pressure elevation is expected to have a protective effect on the blood 
vessels. In addition, ACE serves as a kininase II (Sharma, 2009). Because kininase II 
degrades bradykinin, a vasodilator, inhibition of ACE (or kininase II) by CCH causes 
bradykinin accumulation in the body. Bradykinin activates endothelial nitric oxide synthase 
(eNOS) and increases the production of nitric oxide (NO), a vasodilator. In this manner, 
CCH was expected to have a vasoprotective function—a novel tertiary function of foods— 
through its ACE inhibitory activity. 
2. Hypotensive effects of chicken collagen hydrolysate in subjects with 
hypertension 
Arteriosclerosis and hypertension are closely associated with each other. If strong 
pressure is applied continuously to an artery because of hypertension, the arterial walls 
are damaged and blood cholesterols infiltrate the walls through the damaged areas and 
cause arteriosclerosis. In addition, advanced arteriosclerosis narrows the blood vessels 
and causes blood flow to deteriorate. The heartbeat is then enhanced to improve blood 
flow, and this causes the blood pressure to increase. In this manner, hypertension 
accelerates arteriosclerosis and produces a vicious cycle. If we could alleviate 
hypertension, we would thus also be able to ameliorate arteriosclerosis. We therefore 
initially conducted a clinical trial to verify the hypotensive effect of CCH in humans 
(Kouguchi, 2008). 
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Fig. 2. Process of production of chicken collagen hydrolysate (CCH). Chicken legs are used 
as the basic ingredient and are treated with acid and then hot water to extract collagen, 
which was then processed with proteases. The resulting low-molecular-weight collagen 
peptides are then dried and powered for subsequent use as CCH.  
2.1 Subjects 
Subjects for the test were 120 healthy, antihypertensive drug–free, adult males and females 
with mild hypertension or high-normal blood pressure. The subjects (males, 59; females, 61) 
were randomly assigned to two groups. No significant differences in subject characteristics, 
including sex, age, height, body weight, body mass index, systolic blood pressure, diastolic 
blood pressure, and pulse rate, were observed between the two groups (P > 0.2). 
The study was approved by the institutional review board and was performed under the 
close supervision of the study investigators. The subjects were well informed about the 
test contents and methods by the study investigators, and they provided written 
informed consent to protect their rights in accordance with the spirit of the Declaration 
of Helsinki. 
2.2 Experimental diets 
A drink containing CCH (hereafter, referred to as the test food) or its counterpart without 
CCH (hereafter, referred to as the placebo) was used in the experiment. The test food 
contained 2.9 g of CCH; for the placebo, the raw material composition was the same as that 
of the test food, but without the CCH. 
2.3 Trial design 
The trial was designed as a placebo-controlled, double-blind, parallel-group comparison 
study. The study ran for a total of 18 weeks: 2 observational weeks before the treatment 
(pre-treatment observation period), a 12-week treatment period, and 4 weeks for post-
treatment observation (post-treatment observation period). All subjects were given a bottle 
of drink daily during the treatment period. All subjects were directed not to change their 
daily diets and exercise regimens (Fig.3). They were advised strongly not to overeat, over-
drink, or over-exercise. 
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Fig. 3. Clinical trial schedule for CCH administration. The 120 subjects were assigned to two 
groups and given the experimental or placebo diet for 12 weeks. Blood pressure was 
measured a total of 11 times in the course of the experiment: twice in the pre-treatment 
observation period, 7 times in the treatment period, and twice in the post-treatment 
observation period.  
2.4 Measurement of blood pressure 
Blood pressure was measured a total of 11 times in the course of the experiment: twice in the 
pre-treatment observation period, 7 times in the treatment period, and twice in the post-
treatment observation period. The subjects were kept at rest for at least 10 min before the 
measurement. Blood pressure in the left cubital fossa was measured while the subjects were 
seated. Blood pressure was measured more than once with a mercury manometer. The 
average value of 2 stable measurements (i.e. when the difference of the values was less than 
5 mmHg) was recorded as the value recorded. Pulse rate was measured once at each visit. 
The subjects’ condition was also interviewed by a doctor at the time of measurement of 
blood pressure. 
2.5 Results 
Systolic blood pressures in the test food group were non-significantly lower (P < 0.1) than 
those of the placebo group after 2 weeks of treatment and were significantly lower (P < 0.05) 
than in the placebo group after 12 weeks of treatment (Fig. 4). In the test food group, in 
comparison with the mean pre-treatment blood pressure (139.7 mm Hg), the blood pressure 
was significantly lower after 2 weeks (133.9 mm Hg; P < 0.001), 4 weeks (135.7 mm Hg; P < 
0.01), 6 weeks (134.6 mm Hg; P < 0.001), 8 weeks (134.4 mm Hg; P < 0.01), 10 weeks (134.6 
mm Hg; P < 0.001), and 12 weeks (133.5 mm Hg; P < 0.001). After 2 weeks of treatment, the 
blood pressure in the test food group was 135.5 mm Hg; this was non-significantly lower 
than the pre-treatment blood pressure (P < 0.1). In the placebo group, blood pressure after 6 
weeks of treatment (135.9 mm Hg) was significantly lower than the pre-treatment blood 
pressure (139.8 mm Hg) (P < 0.05). 
2.6 Discussion 
Blood pressures in the test food group decreased continuously during the treatment period. 
Because the compositional difference between the test food and placebo in this experiment 
was only the presence or the absence of CCH, the observed antihypertensive effect was 
considered to be due to CCH treatment. We had previously confirmed that CCH exhibits 
ACE inhibitory activity and antihypertensive effects in rats (Saiga, 2008). The results of this 
study indicated that CCH had a similar antihypertensive effect in humans. Moreover, on 
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medical examination some subjects reported a dry cough. Dry cough is typically observed 
with ACE inhibitor administration and is attributed to bradykinin accumulation in the body. 
This raises the possibility that the CCH inhibited kininase II and thus caused accumulation 
of bradykinin, a vasoprotector, which then induced NO production via the stimulation of 
eNOS. The results suggest that CCH exerts vasoprotective effects by ameliorating blood 
pressure in humans. 
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Fig. 4. Time-course of changes in systolic blood pressure in the subjects. Systolic blood 
pressures in the test food group were non-significantly lower than those in the placebo 
group after 2 weeks of treatment and were significantly lower than in the placebo group 
after 12 weeks of treatment. In comparison with the pre-treatment blood pressure (mean of 
the values at −2, −1, and 0 weeks), the blood pressure in the test food group was 
consistently  and significantly lower throughout the treatment period. Data are mean ± SE 
values . + P< 0.1, # P< 0.05 versus placebo group. † P< 0.1, ＊P< 0.05, ＊＊ P< 0.01, ＊＊＊ 
P< 0.001 versus pre-treatment blood pressure.  
In our previous in vitro studies, we found that CCH treatment of human umbilical vein 
endothelial cells directly increased eNOS activation (data not shown). When eNOS 
expressed in vascular endothelial cells is activated, the cells produce NO. The NO 
functions as a signal to relax adjacent vascular smooth muscle cells; consequently, this 
dilates arteries and increases blood flow. Other than NO, vascular endothelial cells excrete 
vasoactive substances such as endothelin, a vasopressor, and maintain the balance of 
constriction and dilation of blood vessels. NO production via eNOS is particularly 
important in maintaining the homeostasis of blood vessels. Taken together, these findings 
indicate that oral administration of CCH improves blood pressure by inhibiting ACE and 
protects blood vessels by inducing NO production, thereby inhibiting the development of 
arteriosclerosis. 
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3. CCH treatment improves vascular endothelial function in rats and thus 
exerts protective effects on organs 
The clinical trial described in the preceding section suggested that CCH protects the blood 
vessels by inducing NO production. Therefore, we next directly investigated the 
vasodilatory effect of CCH ex vivo by using rat blood vessels. We administered L-NG-
nitroarginine methyl ester (L-NAME), an NO synthesis inhibitor, to rats to trigger vascular 
endothelial dysfunction. We then tested whether prolonged CCH treatment of the rats 
would restore their endothelial function (Zhang, 2010). 
3.1 Experimental animals 
Thirty-six male WKY rats (10 weeks old) were randomly allocated to three groups. The first 
group (control group) received untreated chow and drinking water. The second group (L-
NAME group) received L-NAME in their drinking water (0.5 g/L) for 8 weeks. The third 
group (L-NAME＋CCH group) received L-NAME in their drinking water and CCH (2.0 
g/kg daily) via a metal oral Zonde needle. All animal procedures were performed in 
accordance with the Animal Experimentation Guidelines of the Japanese Association for 
Laboratory Animal Science and were approved by the Animal Use and Care Committee of 
Nippon Meat Packers, Inc. 
3.2 Vasorelaxation assay 
A vasorelaxation assay was performed on the tissue of eight or nine rats from each group 
after 8 weeks of treatment. The rats were anesthetized with diethyl ether and the thoracic 
aorta was removed. The surrounding connective tissue and fat were carefully removed from 
the thoracic aorta, which was then cut into 2- to 3-mm-wide rings. Segments of thoracic 
aorta were mounted between two steel hooks in isolated tissue chambers containing Krebs-
Henseleit solution at 37 °C. The isometric tension was recorded with an isometric force-
displacement transducer. After an equilibration period, L-norepinephrine bitartrate was 
added to cause contraction. This was followed by the addition of cumulative doses of 
acetylcholine chloride to the bath solution to produce relaxation. Vascular relaxation was 
expressed as a percentage of tension development (Fig.5). 
3.3 Results 
After 8 weeks of treatment, the survival rate of the L-NAME group rats, which had received 
L-NAME in their drinking water, was 66.7% of that of the control rats. However, rats that 
had ingested CCH (L-NAME＋CCH group) had a significantly better survival rate (91.7% of 
that of the control group) than the L-NAME rats (P < 0.05) (Fig.6). During all of the 
experiments, monitoring revealed that the rats drank 17 to 30 mL of water and ate 16 to 30 g 
of chow every day, confirming that their drinking and eating patterns were unaffected by 
the treatment protocols. Body weight gains did not differ among groups (data not shown). 
We measured the vasorelaxant effects of CCH treatment after 8 weeks of treatment (Fig. 7). 
Treatment with acetylcholine chloride caused concentration-dependent relaxation of the 
thoracic aorta preparations from all groups after the preparations had been caused to 
contract by the addition of L-norepinephrine bitartrate. The acetylcholine chloride induced a 
relaxation response in the thoracic aortas from the L-NAME group (12.7% vasorelaxation); 
this was significantly less than that in preparations from the control group (69.5%). 
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Compared with that of the L-NAME group, vasorelaxation of the thoracic aortas from the L-
NAME＋CCH group (36.0%) was significantly improved by long-term administration of 
CCH (P < 0.05). 
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Fig. 5. Schematic of the Magnus apparatus. The excised rat thoracic aorta was cut into 2- to 
3-mm-wide rings and the segments were mounted between two steel hooks in isolated 
tissue chambers containing Krebs-Henseleit solution at 37C. Drops of L-norepinephrine 
bitartrate were then added to the tissue chamber to cause the aorta to contract. This was 
followed by the addition of various doses of acetylcholine chloride to trigger aortic 
relaxation. The electrical signals for this contraction–relaxation reaction were amplified via a 
transducer and recorded.  
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Fig. 6. Survival rates of rats during the test period. Eight weeks into the test period, the 
survival rate of the L-NAME + CCH group was significantly higher than that of the L-
NAME group. Data are mean ± SE values (n=12 rats). ＊ P< 0.05 versus L-NAME group.  
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Fig. 7. Vasorelaxation of rat thoracic aortas over the 8 weeks of the test period . Treatment 
with acetylcholine chloride caused concentration-dependent relaxation of the thoracic aorta 
preparations from all groups.  Especially at high acetylcholine concentrations,  
vasorelaxation  was significantly higher in the L-NAME + CCH group than in the L-NAME 
group. Data are mean ± SE values (n=8-9 rats). ＊ P< 0.05 versus L-NAME group.  
3.4 Discussion 
We found that CCH treatment improved vascular endothelial function. Acetylcholine 
activates eNOS expressed in vascular endothelial cells and induces NO production, thereby 
dilating blood vessels. In L-NAME-treated rats, the vasodilation response associated with 
NO production induced by an acetylcholine stimulus was inhibited; however, CCH 
treatment improved this response. As stated earlier, our previous studies have confirmed 
that CCH activates eNOS in vascular endothelial cells in vitro; this result was again 
supported by our study. In essence, therefore, CCH treatment strongly activated eNOS, 
promoted NO production, and thus triggered a vasodilatory response. 
Moreover, the survival curves showed that the survival rate of L-NAME-treated rats was 
significantly enhanced by CCH administration. This may have been because CCH treatment 
alleviated the various organ failures caused by L-NAME-induced vascular disorders. We 
previously conducted the same experiment by using a higher concentration of L-NAME (1 
g/L) and prepared tissue sections for observation. We identified substantial tissue damage 
associated with L-NAME treatment in the blood vessels, kidney, and heart ; this damage 
was alleviated by CCH treatment (Fig. 8). The substantial fibrosis observed, especially in the 
heart and liver, was relieved by CCH treatment. Although further investigations of this 
attenuation effect of CCH treatment on tissue damage are required, we consider that it 
results from tissue protection via the vasoprotective effects of CCH. 
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Fig. 8. Tissue sections of  blood vessels (A, ×160), kidney (B, ×80) and heart (C, ×80) after 
treatment with L-NAME at a high concentration (1 g/L). Tissues were stained with Masson 
trichrome. These sections are from a similarly designed previous experiment of ours. 
Significant tissue damage caused by L-NAME was observed in the blood vessels, kidneys, 
and heart tissues, whereas CCH treatment alleviated these damages. Arrows indicate signs 
of fibrosis.  
4. CCH treatment inhibits proinflammatory cytokine expression in a mouse 
model of arteriosclerosis 
Previous studies have indicated that CCH exerts vasoprotective effects and thus organ 
protective effects. We therefore investigated the effects of CCH in an atherosclerosis mouse 
model, C57BL/6.KOR-ApoEsh1. This mouse is spontaneously hyperlipidemic and 
characteristically has high total cholesterol (TC) levels and arteriosclerotic lesions. Using this 
mouse model, we examined the changes in blood cholesterol levels and proinflammatory 
cytokine expression in response to prolonged CCH treatment (Zhang, 2010). 
4.1 Experimental animals 
Eighteen male C57BL/6.KOR-ApoEshl mice (7 weeks old) were randomly allocated to two 
groups (n = 9) and fed on a normal diet or a diet supplemented with 10% CCH for 12 weeks. 
At the end of the 12-week experiment, the mice were sacrificed, blood was obtained from 
their veins, and tissues were collected for further analysis. All animal procedures were 
performed in accordance with the Animal Experimentation Guidelines of the Japanese 
Association for Laboratory Animal Science and were approved by the Animal Use and Care 
Committee of Nippon Meat Packers, Inc. 
www.intechopen.com
 Vasoprotective Effect of Foods as Treatments: Chicken Collagen Hydrolysate 
 
567 
4.2 Measurement of plasma and hepatic lipids 
Levels of TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-
density lipoprotein cholesterol (HDL-C) in the plasma and liver were determined. Total 
lipids extracted from the liver were also analyzed. 
In addition, plasma levels of interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 
(sICAM-1), and tumor necrosis factor-α (TNF-α) were measured by ELISA. 
4.3 Observation of tissue sections 
At the end of the 12-week test period, the thoracic aorta and liver were excised from the 
dissected rats and were fixed in formalin, paraffin-embedded, and sliced with a microtome 
to prepare thin sections, which were then stained with Oil Red O or hematoxylin-eosin for 
histological observation. 
4.4 Results 
The mice were treated with CCH for 12 weeks and then sacrificed for analysis. Compared 
with those in the controls, the amounts of plasma TC and hepatic lipid and TG in the CCH 
group were reduced by 14.4%, 24.7%, and 42.8%, respectively (Table 1). However, CCH 
administration had no obvious influence on the concentrations of TG, LDL-C, and HDL-C in 
the plasma or of TC in the liver. 
 
 
Plasma (mg/100ml) Liver (mg/g)
TC TG LDL-C HDL-C Lipid TC TG
Control 1208±93 308±72 678±68 10.2±1.5 75.3±6.6 0.31±0.11 4.9±2.4
10% CCH 880±73 306±64 550±80 11.3±0.9 56.7±4.8 0.27±0.07 2.8±1.5䠆䠆䠆
 
 
 
Table 1. Effect of CCH treatment on plasma concentrations of TC, TG, LDL-C, and HDL-C 
and on hepatic total lipid, TC, and TG in C57BL/6.KOR-ApoEsh1 mice at the end of the 12-
week test period. Plasma TC, hepatic total lipid, and hepatic TG concentrations were 
significantly lower in the 10% CCH group than in the control group. Data are mean ± SE 
values (n=9 mice). ＊ P< 0.05 versus L-NAME group.  
We also investigated the effects of CCH treatment on plasma proinflammatory cytokine 
levels in C57BL/6.KOR-ApoEshl mice. Administration of CCH resulted in decreases in 
plasma levels of IL-6 (by 43.4%, P < 0.01), sICAM-1 (by 17.9%, P < 0.05), and TNF-α (by 
24.1%, P < 0.01) (Fig.9). 
To investigate whether CCH had a preventive and therapeutic effect on arteriosclerosis, 
atherosclerotic lesions in the aorta were observed by microscopy with Oil Red O staining 
(Fig.10). There were no obvious differences in the aortas of the CCH and control groups. 
We then tested whether CCH treatment had alleviated liver damage in the C57BL/6.KOR-
ApoEshl mouse model. Sections of paraffin-embedded liver were stained with 
hematoxylin-eosin or Oil Red O. Treatment with 10% CCH for 12 weeks decreased the 
abundance of diffuse lipid droplets and fat vacuoles compared with that in the control 
group (Fig.10). 
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Fig. 9. Effect of CCH treatment on plasma proinflammatory cytokine levels in 
C57BL/6.KOR-ApoEsh1 mice at the end of the 12-week test period. Interleukin-6 (IL-6) (A), 
soluble intercellular adhesion molecule-1 (sICAM-1 ) (B), tumor necrosis factor alpha (TNF-
α) (C). The levels of all plasma proinflammatory cytokines were significantly lower in the 
10% CCH group than in the control group. Data are mean ± SE values (n=9 mice). ＊ P< 
0.05, ＊＊ P< 0.01 versus control group.  
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Fig. 10. Tissue sections of aortic root (A) and liver (B and C) at the end of the 12-week test 
period. Tissues were stained with Oil Red O (A, ×80; C, ×140) or hematoxylin-eosin (B , 
×140). No obvious change was observed in the aortic root of the 10% CCH group; however, 
diffuse lipid droplets and fat vacuoles in the livers of the treatment group were less 
abundant than in those of the control group.  
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4.5 Discussion 
Our results suggested that, as well as lowering plasma TC, CCH had a lipid-lowering effect 
through regulation of hepatic lipid biosynthesis to suppress TG levels. In humans, collagen-
specific peptides are absorbed into the blood as a result of CCH treatment  (Iwai, 2009). 
Once absorbed into the body, the CCH peptides function as regulatory factors to influence 
cholesterol homeostasis. This effect may have contributed to the decrease in the abundance 
of lipid droplets and fat vacuoles observed in the liver tissues. 
Because inflammation plays an important role in the development of arteriosclerosis, 
inflammatory markers were also examined to investigate the anti-inflammatory function of 
dietary intervention. IL-6, sICAM-1, and TNF-α are the major proinflammatory cytokines 
secreted by adipocytes. At the same time, NO inhibits the expression of these 
proinflammatory cytokines in the vascular endothelium. Our previous studies indicate that 
orally ingested CCH induces NO production in the body. Hence, the results imply that CCH 
treatment downregulates several proinflammatory cytokines via NO production, thereby 
having beneficial effects on the fat tissues. Further detailed investigations are, however, 
necessary to elucidate more of the direct effects of CCH on fat cells. 
Unfortunately, no direct therapeutic effect of CCH on arteriosclerotic plaques was 
observed in this study. Nevertheless, the data demonstrated that CCH treatment 
substantially reduced both the total lipid content in the liver and the production of 
proinflammatory cytokines such as IL-6, TNF-α, and sICAM-1 in a mouse model highly 
susceptible to arteriosclerosis. High levels of expression of these factors lead to the 
progression of arteriosclerosis. From this perspective, long-term CCH treatment may  
be effective as a simple dietary, rather than drug, treatment for preventing 
arteriosclerosis. 
5. Conclusion: The availability of collagen peptides as a food providing anti-
atherogenesis via a vasoprotective effect 
It has been frequently reported that externally applied collagen peptides help to  increase 
water retention owing to their high water retentivity. On the other hand, the functionality of 
orally ingested collagen is not fully understood. However, much of the evidence reported in 
recent years, including the results of this study, supports the specific physiological activities 
of collagen absorbed by the body. 
In this study, we examined the impacts of collagen peptides on blood vessels from various 
perspectives. We demonstrated that collagen peptides exhibit vasoprotective functions via 
NO production and effectively protect against atherogenesis. 
Functional foods will not replace pharmaceuticals. However, what humans continue to do 
regularly for survival is to eat. Whereas a balanced diet obviously supports healthy life, 
elucidation of the tertiary function of food ingredients by precisely following their 
mechanisms is a long-term mission for food researchers. We focused on collagen and 
analyzed the whole process from development of, to research into, novel chicken-derived 
collagen peptides. We clarified the efficacy of vasoprotection, which is a novel tertiary 
function of collagen peptides. We intend to continue our efforts to demonstrate the 
beneficial functionalities of collagen in the hope of improving the global quality of life 
through the consumption of this food product. 
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